How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24%Zacks Investment Research • 11/26/25
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?Zacks Investment Research • 11/10/25
Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/25
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?Zacks Investment Research • 10/21/25
Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million SharesGlobeNewsWire • 10/20/25
Keros Therapeutics Announces Plan for Return of $375 Million in Excess CapitalGlobeNewsWire • 10/15/25
Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual MeetingGlobeNewsWire • 09/08/25
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board RefreshmentPRNewsWire • 08/21/25
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 08/20/25
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/06/25
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of ElriterceptGlobeNewsWire • 07/17/25
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return ProposalPRNewsWire • 06/09/25
Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/06/25